Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04929236 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
A Phase 3 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Octapharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT04929236: Recruiting Phase 3 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Octapharma.
NCT04929236 is a Phase 3 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Octapharma. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04929236, a Phase 3 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Primary Outcome
Evaluate the efficacy of two PANZYGA dose regimens in pediatric CIDP patients based on change in CIDP symptoms, measured by the Modified Rankin Score. The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 6.
Conditions Studied
Interventions
- DRUG Panzyga
Study Locations (6)
Alabama
- Octapharma Research Site - Birmingham
California
- Octapharma Research Site - Orange
Kentucky
- Octapharma Research Site - Louisville
Pennsylvania
- Octapharma Research Site - Philadelphia
Texas
- Octapharma Research Site - Houston
Virginia
- Octapharma Research Site - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
What NCT04929236 shows while recruiting
NCT04929236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Pediatric Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which Panzyga is the first listed.
NCT04929236 lists 6 locations in 6 states (Alabama, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT04929236 about?
NCT04929236 is a clinical study titled "Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients". Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
What is the current status of trial NCT04929236?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2023-10-01. Estimated completion is 2026-06.
What conditions does trial NCT04929236 study?
This clinical trial studies the following conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT04929236?
The interventions under investigation include: Panzyga (DRUG).
Who is sponsoring clinical trial NCT04929236?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04929236 being conducted?
This trial has 6 study locations across Alabama, California, Kentucky, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04929236's enrollment target sits among peer trials
30 1918th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI